April 2021 in “Bioscientia Medicina Journal of Biomedicine and Translational Research” Hydroxychloroquine may help COVID-19 patients with lupus.
April 2021 in “Bioscientia Medicina Journal of Biomedicine and Translational Research” Patients with lupus nephritis and COVID-19 can improve with proper treatment.
August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
35 citations
,
November 2019 in “Scientific Reports” Shikimic acid promotes hair growth.
54 citations
,
October 2019 in “Cochrane library” Some drugs may reduce prostatitis symptoms short-term with few side effects.
1 citations
,
January 2025 in “OBM Geriatrics” Platelets play a key role in the immune system and their lifespan and aging are important for developing new treatments.
COVID-19 can cause skin problems and affect dermatology treatments, with recommendations for skin care and cautious use of certain drugs.
December 2019 in “University of Malaya Students Repository” Mimosine from Leucaena leucocephala can enhance biodiesel stability.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
9 citations
,
June 2022 in “Microorganisms” We need safe, affordable drugs to fight coronaviruses effectively.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
8 citations
,
January 2023 in “Journal of Research in Pharmacy” Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.
December 2023 in “Journal of Multiple Sclerosis and Neuroimmunology” Teriflunomide can cause hair thinning.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
May 2018 in “Digital ProScholar Media eBooks” The new fluoroquinolone effectively fights certain bacteria.
42 citations
,
April 2021 in “Pharmaceuticals” Five FDA-approved drugs may help block COVID-19 virus entry.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
2 citations
,
August 2024 in “Heliyon” Metformin may help mild COVID-19 cases, while Oseltamivir, Tamoxifen, and Dexamethasone are suggested for severe cases.